Imperial College London
Alternate

ProfessorCharlotteBevan

Faculty of Medicine, Department of Surgery & Cancer

Professor of Cancer Biology
 
 
 
//

Contact

 

charlotte.bevan Website

 
 
//

Assistant

 

Mrs Suzy Ford +44 (0)20 7594 2135

 
//

Location

 

139ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Constantin:2022:10.1038/s41388-022-02347-1,
author = {Constantin, TA and Greenland, KK and Varela-Carver, A and Bevan, CL},
doi = {10.1038/s41388-022-02347-1},
journal = {Oncogene},
pages = {3303--3315},
title = {Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer},
url = {http://dx.doi.org/10.1038/s41388-022-02347-1},
volume = {41},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Transcriptional deregulation has emerged as a hallmark of several cancer types. In metastatic castration-resistant prostate cancer, a stage in which systemic androgen deprivation therapies fail to show clinical benefit, transcriptional addiction to the androgen receptor is maintained in most patients. This has led to increased efforts to find novel therapies that prevent oncogenic transactivation of the androgen receptor. In this context, a group of druggable protein kinases, known as transcription associated cyclin-dependent kinases (tCDKs), show great potential as therapeutic targets. Despite initial reservations about targeting tCDKs due to their ubiquitous and prerequisite nature, preclinical studies showed that selectively inhibiting such kinases could provide sufficient therapeutic window to exert antitumour effects in the absence of systemic toxicity. As a result, several highly specific inhibitors are currently being trialled in solid tumours, including prostate cancer. This article summarises the roles of tCDKs in regulating gene transcription and highlights rationales for their targeting in prostate cancer. It provides an overview of the most recent developments in this therapeutic area, including the most recent clinical advances, and discusses the utility of tCDK inhibitors in combination with established cancer agents.
AU  - Constantin,TA
AU  - Greenland,KK
AU  - Varela-Carver,A
AU  - Bevan,CL
DO  - 10.1038/s41388-022-02347-1
EP  - 3315
PY  - 2022///
SN  - 0950-9232
SP  - 3303
TI  - Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
T2  - Oncogene
UR  - http://dx.doi.org/10.1038/s41388-022-02347-1
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000795517600002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.nature.com/articles/s41388-022-02347-1
UR  - http://hdl.handle.net/10044/1/98578
VL  - 41
ER  -
Download